Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19

Background and Aim: Tocilizumab, a humanized anti-IL-6 receptor antibody, has been used to treat severely to critically ill patients with COVID-19. A living systematic review with meta-analysis of recent RCTs indicates that the combination therapy of corticosteroids and tocilizumab produce better ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Shoji, Yoshizaki, Kazuyuki, Uno, Kazuko, Kitajima, Heita, Arai, Tsuyoshi, Tamura, Yoshitaka, Morishita, Hiroshi, Matsuoka, Hiroto, Han, Yuki, Minamoto, Seijiro, Hirashima, Tomonori, Yamada, Tomoki, Kashiwa, Yozo, Kameda, Makoto, Yamaguchi, Seiji, Tsuchihashi, Yasunari, Iwahashi, Mitsuhiro, Nakayama, Emi, Shioda, Tatsuo, Nagai, Takayuki, Tanaka, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494777/
https://www.ncbi.nlm.nih.gov/pubmed/34631752
http://dx.doi.org/10.3389/fmed.2021.734838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494777/
https://www.ncbi.nlm.nih.gov/pubmed/34631752
http://dx.doi.org/10.3389/fmed.2021.734838

Ejemplares similares